HRTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Heron Therapeutics Inc. (HRTX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite mixed financial performance, the company shows strong growth in its Acute Care franchise, positive revenue guidance for 2026, and significant pre-market price momentum. The technical indicators and options sentiment suggest potential upside, making it a suitable investment for long-term growth.
The MACD is negative and contracting, indicating a bearish trend. RSI is neutral at 54.579, suggesting no clear overbought or oversold conditions. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are Pivot: 1.181, R1: 1.288, S1: 1.074, R2: 1.354, S2: 1.008. However, the stock has shown strong pre-market momentum with a 14.81% gain.
Acute Care franchise revenue grew 57.3% YoY in Q4 2025, indicating strong market demand.
Positive 2026 revenue guidance of $173M-$183M.
Successful financing completion and strong liquidity with $46.6M in cash and short-term investments.
Pre-market price surge of 14.81%, indicating strong investor interest.
Financial performance in Q4 2025 showed a slight revenue decline (-0.47% YoY) and a significant drop in net income (-180.64% YoY).
Gross margin dropped to 0, reflecting operational inefficiencies.
Bearish technical indicators with MACD and moving averages signaling caution.
In Q4 2025, revenue slightly declined by -0.47% YoY to $40.59M, while net income dropped significantly by -180.64% YoY to -$2.95M. EPS fell to -$0.02, down 200% YoY. However, the Acute Care franchise showed strong growth, and the company has provided optimistic revenue guidance for 2026.
No recent analyst rating or price target changes are available. However, the company's strong Acute Care franchise growth and positive revenue guidance may attract favorable ratings in the future.
